Hydrochlorothiazide

Generic Name: Hydrochlorothiazide

Brand Names: Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac

Drug Type: Small Molecule

Chemical Formula: C_₇H_₈ClN_₃O_₄S_₂

CAS Number: 58-93-5

Unique Ingredient Identifier: 0J48LPH2TH

Background: Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

Hydrochlorothiazide was granted FDA approval on 12 February 1959.

Indication: Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions: Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke

Clinical Trials

Empagliflozin and Sympathetic Nerve Traffic

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Hydrochlorothiazide 25 mg
Drug: Empagliflozin

First Posted Date: 2017-08-21

Last Posted Date: 2020-07-14

Lead Sponsor: Profil Institut für Stoffwechselforschung GmbH

Target Recruit Count: 75

Registration Number: NCT03254849

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany

Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)

Phase 3

Conditions: Hypertension

Interventions: Drug: Peri
Drug: HCTZ

First Posted Date: 2017-08-15

Last Posted Date: 2017-08-15

Lead Sponsor: Ospedale San Raffaele

Target Recruit Count: 300

Registration Number: NCT03249285

Locations: 🇮🇹
Azienda Sanitaria 6, Livorno, Italy
🇮🇹
Azienda Ospedaliero - Universitaria S. Maria della Misericordia, Udine, Italy
🇮🇹
San Raffaele Hospital, Milan, Italy

Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans

Phase 1

Terminated

Conditions: Hypertension,Essential

Interventions: Drug: Captopril Pill
Drug: Enalapril Pill
Drug: Hydrochlorothiazide

First Posted Date: 2017-06-07

Last Posted Date: 2024-02-28

Lead Sponsor: Penn State University

Target Recruit Count: 10

Registration Number: NCT03179163

Locations: 🇺🇸
Pennsylvania State University, University Park, Pennsylvania, United States

A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein

Phase 4

Completed

Conditions: Chronic Kidney Diseases

Interventions: Drug: Amiloride
Drug: Hydrochlorothiazide

First Posted Date: 2017-05-31

Last Posted Date: 2020-09-18

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 40

Registration Number: NCT03170336

Locations: 🇨🇳
Nephrology Dept,Guangdong General Hospital, Guangzhou, Guangdong, China

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

Phase 4

Completed

Conditions: High Blood Pressure

Interventions: Drug: Aliskiren 150 mg
Drug: Placebo
Drug: HCTZ
Drug: Aliskiren 300 mg

First Posted Date: 2017-04-14

Last Posted Date: 2017-08-25

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 31

Registration Number: NCT03115853

Locations: 🇺🇸
VUMC, Nashville, Tennessee, United States

Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System

Phase 4

Terminated

Conditions: Anxiety
Hypertension

Interventions: Drug: Clonidine Pill
Drug: Hydrochlorothiazide

First Posted Date: 2017-04-12

Last Posted Date: 2024-07-29

Lead Sponsor: University of Iowa

Target Recruit Count: 35

Registration Number: NCT03109795

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States

The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients

Not Applicable

Conditions: Chronic Kidney Disease
Secondary Hyperparathyroidism

Interventions: Drug: Hydrochlorothiazide
Drug: Furosemide

First Posted Date: 2017-03-17

Last Posted Date: 2017-10-26

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 52

Registration Number: NCT03082742

Locations: 🇧🇷
Hospital das Clinicas, Sao Paulo, SP, Brazil

Hydrochlorothiazide for Kidney Stone Recurrence Prevention

Phase 3

Completed

Conditions: Nephrolithiasis

Interventions: Drug: 50.0 mg hydrochlorothiazide
Drug: 12.5 mg hydrochlorothiazide
Drug: 25.0 mg hydrochlorothiazide
Drug: Placebo oral capsule

First Posted Date: 2017-02-20

Last Posted Date: 2024-02-01

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 416

Registration Number: NCT03057431

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland
🇨🇭
Ospedale Regionale di Bellinzona e Valli (San Giovanni), Bellinzona, Switzerland
🇨🇭
Kantonsspital Aarau, Aarau, Switzerland

and more 9 locations

Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TWYNSTA(Telmisartan+Amlodipine besylate)
Drug: TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)
Drug: Hydrochlorothiazide